Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRTB-HDT
2025-520745-80-00Phase 2Completed
- Sponsor
- Aurum Institute
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised trial of dovramilast and metformin in pulmonary tuberculosis (TB) and Rifampicin-resistant pulmonary tuberculosis (RR-PTB) (3 arms), sponsored by Aurum Institute. Primary endpoint: Safety, tolerability, and preliminary efficacy of CC-11050 and metformin adjunctive therapies. Started Jan 2025; status: completed.
02
Drugs
dovramilastmetformin
03
Conditions
pulmonary tuberculosis (TB)Rifampicin-resistant pulmonary tuberculosis (RR-PTB)
Beyond the preview
Go deeper on 2025-520745-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520745-80-00.